Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population
- PMID: 19965333
- DOI: 10.1310/hct1005-337
Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical